Loading... Please wait...
Sort by:

therapy-trends-jpg.jpg
Therapy Trends
 reports deliver critical and unbiased intelligence derived from in-depth interviews with the world’s foremost thought leaders on the current and future treatment landscapes in major disease areas. Research is focused on the major battlegrounds for market share and answers critical business questions about potential product positioning and competitiveness. Through continuous monitoring and frequent re-engagement with stakeholders, the FirstWord Therapy Trends analyst team delivers quarterly updates with each report ensuring insights remain current and relevant.

  • Melanoma: KOL Insight [2017]
    Learn More Melanoma: KOL Insight [2017]
    Are novel therapies set to revolutionise malignant melanoma? Despite advances in the treatment of malignant melanoma (MM), demand still persists for improved modalities and outcomes. Newer targeted and immunotherapy...
  • Multiple Sclerosis: KOL Insight [2017]
    Learn More Multiple Sclerosis: KOL Insight [2017]
    How will Ocrevus reshape the MS treatment landscape? A multitude of recent approvals and launches are changing the way MS is treated, but what does the future hold? Key opinion leaders (KOLs) are excited about...
  • Alzheimer's Disease: KOL Insight [2017]
    Learn More Alzheimer's Disease: KOL Insight [2017]
    Do KOLs see a future for beta-amyloid as a target in Alzheimer’s? Despite the inexorable attrition rate, both big pharma and small biotechs continue to invest in Alzheimer’s disease R&D. Is the amyloid...
  • Prostate Cancer: KOL Insight [2017]
    Learn More Prostate Cancer: KOL Insight [2017]
    How will established and emerging agents reshape the prostate cancer treatment landscape? A multitude of novel therapies have been approved for prostate cancer over the past ten years, but what does the future hold? Key...
  • Ulcerative Colitis: KOL Insight [2017]
    Learn More Ulcerative Colitis: KOL Insight [2017]
    Will oral therapies transform the treatment of ulcerative colitis? With Pfizer’s Xeljanz (tofacitinib) pending approval in the US, new oral therapies are set to transform the ulcerative colitis (UC) treatment...
  • Colorectal Cancer: KOL Insight [2017]
    Learn More Colorectal Cancer: KOL Insight [2017]
    Will new targeted therapies transform the treatment of colorectal cancer? Checkpoint inhibitors continue their march into multiple areas of oncology, and are now approved as treatments for colorectal cancer. But while...
  • Type 2 Diabetes Mellitus: KOL Insight [2017]
    Learn More Type 2 Diabetes Mellitus: KOL Insight [2017]
    Will novel therapies transform the treatment of type 2 diabetes? The treatment of type 2 diabetes mellitus has evolved in recent years with introduction of new classes of molecules. While the wide array of treatment...
  • Atopic Dermatitis: KOL insight [2017]
    Learn More Atopic Dermatitis: KOL insight [2017]
    Will targeted therapies transform the treatment of atopic dermatitis? New targeted treatments look set to transform the treatment of moderate to severe atopic dermatitis. As Dupixent (dupilumab; Regeneron/Sanofi) gains...
  • NSCLC: KOL Insight [2017]
    Learn More NSCLC: KOL Insight [2017]
    How will immunotherapy combination regimens impact the NSCLC treatment landscape?  The pace of change in NSCLC shows no sign of abating. Developments in immunotherapy continue to take centre stage, particularly in...
  • Bladder Cancer: KOL Insight [2017]
    Learn More Bladder Cancer: KOL Insight [2017]
    How will immune checkpoint inhibitors transform the treatment of Bladder Cancer? Significant progress has been made over the past decade in bladder cancer as a host of new targeted therapies have emerged from the...
  • Chronic Lymphocytic Leukaemia (CLL): KOL Insight [2017]
    Learn More Chronic Lymphocytic Leukaemia (CLL): KOL Insight [2017]
    Will novel targeted therapies establish a place in CLL treatment pathways?  Chemo-immunotherapy regimens incorporating Rituxan/MabThera have traditionally been at the forefront of CLL treatment. How is this all set...
  • Psoriasis: KOL Insight [2017]
    Learn More Psoriasis: KOL Insight [2017]
    Will biosimilar anti-TNFs prevent novel therapies from gaining traction?  As the use of biosimilar anti-TNFs continues to expand access , and lower the costs of, biologic therapies in the treatment for psoriasis,...
  • Renal Cell Carcinoma: KOL Insight [2017]
    Learn More Renal Cell Carcinoma: KOL Insight [2017]
    How will new combination regimens impact the RCC treatment landscape? The treatment of advanced RCC has been transformed in recent years as VEGF, TKI and mTOR inhibitors have taken centre stage. KOLs now argue that the...
  • Multiple Myeloma: KOL Insight [2017]
    Learn More Multiple Myeloma: KOL Insight [2017]
    Will novel therapies transform the treatment of Multiple Myeloma? In recent years, there has been significant progress in the prognosis for newly diagnosed multiple myeloma (MM) patients. While the current range of...
  • Systemic Lupus Erythematosus (SLE): KOL Insight
    Learn More Systemic Lupus Erythematosus (SLE): KOL Insight
    Will novel therapies revolutionise the treatment of SLE? With the approval of GSK’s Benlysta (belimumab) came the dawn of targeted therapy in the treatment of systemic lupus erythematosus (SLE). Roche’s...
  • CAR-T Therapy in Haematological Malignancy: Early Stage Outlook: KOL Insight [2017]
    Learn More CAR-T Therapy in Haematological Malignancy: Early Stage Outlook: KOL Insight [2017]
    Will CAR-T cell therapies shape the treatment of blood cancers in the next decade? Anti-CD19 CAR-T cell therapies have demonstrated unprecedented response rates across patient subgroups of acute lymphocytic leukaemia...
  • Nonalcoholic Steatohepatitis (NASH): KOL Insight [2017]
    Learn More Nonalcoholic Steatohepatitis (NASH): KOL Insight [2017]
    Will novel therapies revolutionise the treatment of NASH? No drug therapies have been approved for patients with nonalcoholic steatohepatitis (NASH) but how is this set to change within the next five years?...
  •  Ovarian Cancer: KOL Insight [2017]
    Learn More Ovarian Cancer: KOL Insight [2017]
    How will new combination regimens impact the ovarian cancer treatment landscape? Competition is intensifying in the PARP inhibitor space due to the recent approval of Clovis’ Rubraca and Tesaro/Merck & Co...
  • Breast Cancer: KOL Insight [2017]
    Learn More Breast Cancer: KOL Insight [2017]
    How is Ibrance faring? Is Kisqali expected to be a threat? Having dominated the HER2-positive breast cancer space for many years, Roche’s blockbuster drug Herceptin is likely to face the threat of biosimilar...
  • COPD: KOL Insight [2017]
    Learn More COPD: KOL Insight [2017]
    Are closed triple combos expected to change treatment dynamics? New treatment guidelines look set to change the way in which COPD is treated. New guidelines from the Global Initiative for Chronic Obstructive Lung...

customer.service@firstwordpharma.com

All Contents Copyright © 2017 Doctor's Guide Publishing Limited All Rights Reserved